Tesla Electrochem Ltd.
OUR 2021 TASKFORCE TEAM is composed of virologists, molecular biologists, MDs, immunologists, engineers, and epidemiologists. It is our conclusion that the present pandemic challenge relates not only to the SARS-CoV-2 virus but in large part to present and impending damage caused by mRNA vaccines.
To meet the challenge, our interdisciplinary team has created an effective platform, to become a commercial product in May 2021, which mitigates the autoimmune damage which substantial research indicates will result from the use of the mRNA vaccines. Three universities are involved in this development. One in the United States and two in Israel.
The platform is GENEXio. And Tesla Electrochem is:
For updates and further information, contact Tesla Electrochem via our contact page on this website.
Headquarters: Tesla Electrochem Ltd
Korkeakoulunkatu 7 University Street
33720 Tampere, Finland
Tel: +358 3 74118322